InvestSMART

BCAL Diagnostics Limited (ASX:BDX)

ALERT: Price-sensitive ASX Announcement for BDX
Current share price for BDX : $0.081 0.029 (55.77%)+
Announcement
Release
26 Aug 2026 8:57AM
Price at Release
$0.052
Full Release
download
Summary
BCAL Diagnostics Limited, an Australian company focusing on early cancer detection, has increased its stake in Genetic Signatures Ltd to 18.46% by acquiring an additional 8.25% for $1.5 million. This strategic investment aims to broaden BCAL's diagnostic capabilities into infectious diseases, leveraging Genetic Signatures' complementary molecular diagnostics technology. BCAL sees potential in this partnership for enhanced global scalability and growth opportunities, aligning with its current efforts to expand its product portfolio, including the BREASTESTplus™ and Avantect tests.
Key Points
  • BCAL increased its stake in Genetic Signatures Ltd to 18.46%.
  • Acquisition involved 18.75 million shares for $1.5 million.
  • Investment is to enhance BCAL's diagnostic platform and growth.
  • BCAL focuses on early cancer detection and is based in Sydney.
  • BCAL is listed on the Australian Securities Exchange as BDX.
  • Genetic Signatures specializes in molecular diagnostics with 3base® technology.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.